Physician profile
Leyla Daneshdoost
NPI 1871501379
$1,083.57
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $28.01 · 2021: $125 · 2022: $95.55 · 2023: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $124.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $233.90 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $218.98 | 2019-2021 | |
| Novo Nordisk INC | $151.32 | 2019-2023 | |
| Shire North American Group INC | $125.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $95.55 | 2022 | |
| Valeritas, INC. | $76.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $60.00 | 2019 | |
| Ibsa Pharma INC. | $56.74 | 2019 | |
| Amgen INC. | $34.52 | 2019-2020 | |
| Pfizer INC. | $18.09 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leyla Daneshdoost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.